TWI579004B - 有機化合物奈米粉末、其製造方法及懸浮液 - Google Patents

有機化合物奈米粉末、其製造方法及懸浮液 Download PDF

Info

Publication number
TWI579004B
TWI579004B TW102116820A TW102116820A TWI579004B TW I579004 B TWI579004 B TW I579004B TW 102116820 A TW102116820 A TW 102116820A TW 102116820 A TW102116820 A TW 102116820A TW I579004 B TWI579004 B TW I579004B
Authority
TW
Taiwan
Prior art keywords
value
organic compound
particle size
size distribution
pulverization
Prior art date
Application number
TW102116820A
Other languages
English (en)
Chinese (zh)
Other versions
TW201400142A (zh
Inventor
多田貴廣
加賀美和宏
橫田志朗
Original Assignee
活效製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 活效製藥股份有限公司 filed Critical 活效製藥股份有限公司
Publication of TW201400142A publication Critical patent/TW201400142A/zh
Application granted granted Critical
Publication of TWI579004B publication Critical patent/TWI579004B/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members
    • B02C17/205—Adding disintegrating members to the tumbling mill
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/06—Selection or use of additives to aid disintegrating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW102116820A 2012-05-11 2013-05-13 有機化合物奈米粉末、其製造方法及懸浮液 TWI579004B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012108972 2012-05-11

Publications (2)

Publication Number Publication Date
TW201400142A TW201400142A (zh) 2014-01-01
TWI579004B true TWI579004B (zh) 2017-04-21

Family

ID=49550500

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102116820A TWI579004B (zh) 2012-05-11 2013-05-13 有機化合物奈米粉末、其製造方法及懸浮液

Country Status (17)

Country Link
US (1) US9278071B2 (enExample)
EP (1) EP2848243B1 (enExample)
JP (1) JP6054380B2 (enExample)
KR (1) KR101772263B1 (enExample)
CN (1) CN104203217B (enExample)
AU (1) AU2013259150B2 (enExample)
BR (1) BR112014028431B1 (enExample)
CA (1) CA2867236C (enExample)
ES (1) ES2952419T3 (enExample)
IL (1) IL234327B (enExample)
IN (1) IN2014MN02002A (enExample)
MX (1) MX341663B (enExample)
PL (1) PL2848243T3 (enExample)
PT (1) PT2848243T (enExample)
RU (1) RU2613109C2 (enExample)
TW (1) TWI579004B (enExample)
WO (1) WO2013168437A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067045B1 (en) * 2013-11-08 2024-12-04 Activus Pharma Co., Ltd. Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent
CN106102719A (zh) 2014-02-03 2016-11-09 阿普拉诺药品有限公司 天然材料的纳米混悬剂及其制备方法
KR20160133434A (ko) * 2014-03-10 2016-11-22 고쿠리츠다이가쿠호우진 도쿄다이가쿠 수분산성 비정질 입자 및 그 조제 방법
HUE048564T2 (hu) * 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
JP6612081B2 (ja) * 2015-07-31 2019-11-27 東洋精糖株式会社 α−グルコシルルチン含有プテリジン誘導体ナノ粒子の製造方法およびα−グルコシルルチン含有プテリジン誘導体ナノ粒子
EP3331500A1 (en) * 2015-08-04 2018-06-13 Apurano Life Sciences GmbH Nanosuspension containing particles and extract of natural materials
CZ307916B6 (cs) * 2017-05-08 2019-08-21 mcePharma s. r. o. Orodispergovatelná tableta s biodostupným kurkuminem a její použití
CN111253498B (zh) * 2020-03-10 2021-11-09 中国科学院海洋研究所 一种褐藻多糖衍生物纳米胶束的制备
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
CN113209031A (zh) 2021-04-30 2021-08-06 青岛农业大学 一种负载两性霉素B与β-1，3-葡聚糖酶的双靶向复合纳米体系及其制备方法、应用
US20220354761A1 (en) * 2021-04-30 2022-11-10 L'oreal Compositions and methods for treating keratin fibers
CN113620937A (zh) * 2021-08-03 2021-11-09 湖南复瑞生物医药技术有限责任公司 一种高纯度小粒径普仑司特的制备方法
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN116270477B (zh) * 2023-03-13 2025-05-30 华南理工大学 一种无定形态姜黄素纳米颗粒及其制备方法与应用
US20250268918A1 (en) * 2024-02-28 2025-08-28 Tap Pharmaceuticals, Ag Methods for making reduced particle size compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126797A1 (ja) * 2007-04-06 2008-10-23 Activus Pharma Co., Ltd. 微粉砕化有機化合物粒子の製造方法
WO2011118960A2 (ko) * 2010-03-22 2011-09-29 (주)바이오시네틱스 나노입자 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
CA2420597C (en) * 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
JP2006089386A (ja) 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
KR20090027734A (ko) 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
US20110165259A1 (en) 2008-09-19 2011-07-07 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126797A1 (ja) * 2007-04-06 2008-10-23 Activus Pharma Co., Ltd. 微粉砕化有機化合物粒子の製造方法
WO2011118960A2 (ko) * 2010-03-22 2011-09-29 (주)바이오시네틱스 나노입자 제조방법

Also Published As

Publication number Publication date
US20140328917A1 (en) 2014-11-06
CA2867236A1 (en) 2013-11-14
IL234327B (en) 2018-06-28
JP6054380B2 (ja) 2016-12-27
US9278071B2 (en) 2016-03-08
MX2014010772A (es) 2014-10-14
CN104203217A (zh) 2014-12-10
ES2952419T3 (es) 2023-10-31
MX341663B (es) 2016-08-30
CA2867236C (en) 2017-02-28
RU2613109C2 (ru) 2017-03-15
EP2848243B1 (en) 2023-07-12
PT2848243T (pt) 2023-08-02
BR112014028431A2 (pt) 2017-06-27
AU2013259150A1 (en) 2014-08-28
AU2013259150B2 (en) 2016-07-14
RU2014148792A (ru) 2016-06-27
BR112014028431B1 (pt) 2022-01-11
CN104203217B (zh) 2017-02-15
IN2014MN02002A (enExample) 2015-08-07
JPWO2013168437A1 (ja) 2016-01-07
WO2013168437A1 (ja) 2013-11-14
EP2848243A4 (en) 2015-12-23
TW201400142A (zh) 2014-01-01
PL2848243T3 (pl) 2024-04-08
KR20150008376A (ko) 2015-01-22
KR101772263B1 (ko) 2017-08-28
EP2848243A1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
TW201400142A (zh) 有機化合物奈米粉末、其製造方法及懸浮液
EP3057604B1 (en) Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
CN101636150B (zh) 难水溶性医疗用有机化合物微粒子的制造方法
Kanikkannan Technologies to improve the solubility, dissolution and bioavailability of poorly soluble drugs
ES2365012T3 (es) Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
Kumar et al. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design
EP4279071A2 (en) Novel cannabinoid formulations
US20180085308A1 (en) Sustained release cannabinoid formulations
JP4884975B2 (ja) 微粒子含有組成物およびその製造方法
CN1334724A (zh) 纳米颗粒核芯－壳系统及其在药物和化妆品制剂中的应用
AU2018321744A1 (en) Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
BRPI0717721A2 (pt) "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
CN105007898A (zh) 难溶性药物的过饱和的稳定纳米颗粒
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
CA3022834A1 (en) Fulvestrant formulations and methods of their use
WO2023168316A1 (en) Enteric coated dry powdered cannabinoid formulations
Li et al. Development, physical–chemical characterization, and molecular docking simulations of ursolic acid–sodium alginate complexes
CN106999429B (zh) 纳米悬浮剂制剂
JP6579956B2 (ja) 神経変性疾患および他の疾患の治療のための併用治療薬および方法
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
AU2017275844A1 (en) Oral composition of celecoxib for treatment of pain
TW201330849A (zh) 用於鼻內施用褪黑素的藥物組合物
TWI859990B (zh) 玻尿酸衍生物醫藥品組合物及醫藥品組合物
CA3003120C (en) Cannabinoid formulations
HK40009384A (en) Injectable pharmaceutical composition containing meloxicam, and preparation method therefor